The ASIG Pulmonary Arterial Hypertension (PAH) risk assessment algorithm

GO BACK

  • This work arose in response to the need for a sensitive, cost-effective method of screening for pulmonary arterial hypertension (PAH) which occurs in up to 15% of patient with scleroderma. PAH is one of the leading causes of mortality and is one of the major determinants of the substantial healthcare costs associated with scleroderma. International guidelines recommend annual screening for PAH in all patients with scleroderma as while early detection can be challenging, screening is associated with better outcomes. Transthoracic echocardiogram (TTE) alone is insufficiently sensitive for identifying patients at risk of PAH who should be referred for right heart catheterisation (RHC), the gold standard for PAH diagnosis. The DETECT algorithm involved more disease-related features and is still dependent on a TTE.
  • ASIG researchers derived and then validated the ASIG PAH algorithm based on the biomarker, serum NT-proBNP (a peptide released from cardiac myocytes) and pulmonary function tests to measure FVC % predicted and DLCO % predicted.
  • A comparison of the predictive accuracy of the ASIG and DETECT screening algorithms for SSc-PAH with the commonly used ESC/ERS guidelines showed that both algorithms outperform the ESC/ERS guidelines, detecting all patients with PAH. Compared with the DETECT algorithm, the ASIG algorithm had the highest specificity (54.5%) and performed equally well in sensitivity (100%) and NPV (100%) and a little better in PPV (60%).
  • The ASIG algorithm was also associated with cost savings substantially reducing the number of TTE and RHC required compared with TTE.
  • Medicare now allows all patients with SSc to have up to two reimbursed blood tests for NT-proBNP each year as part of PAH screening.
  • The ASIG PAH risk assessment calculator based on the ASIG screening algorithm can be accessed here to assess a patient’s risk for PAH.
Publications:
Quinlivan, A. et al. Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis. Intern Med J 45, 1134-1140, DOI: 10.1111/imj.12890 (2015).
Hao, Y. et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 17, 7, DOI: 10.1186/s13075-015-0517-5 (2015).
Thakkar, V. et al. The Inclusion of N-Terminal pro-Brain Natriuretic Peptide in a Sensitive Screening Strategy for Systemic Sclerosis-Related Pulmonary Arterial Hypertension: a cohort study. Arthritis Res Ther. 2013;15(6):R193. DOI: 10.1186/ar4383
Thakkar, V. et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther 14, R143, DOI: 10.1186/ar3876 (2012).